Drug Channels delivers timely analysis and provocative opinions from Adam J. Fein, Ph.D., the country's foremost expert on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 35,000 subscribers. Learn more...

Tuesday, May 04, 2021

DCI’s Top 15 Specialty Pharmacies of 2020: PBMs Expand Amid the Shakeout—While Walgreens’ Outlook Dims

In Drug Channels Institute's list of the top 15 pharmacies of 2020, we show that many of the largest U.S. market participants are now central-fill mail and specialty pharmacies operated by PBMs and insurers.

To complement that broader ranking, we present below our exclusive list of the top 15 pharmacies based on specialty drug dispensing revenues. You will see that PBMs and insurers have increased their dominance over specialty drug channels. Many of the largest independent companies have been acquired.

As we look ahead, CVS Health and Cigna’s Express Scripts seem best positioned for further growth. However, AllianceRx Walgreens Prime—the joint venture between Walgreens Boots Alliance and Prime Therapeutics—faces significant market share loss.

Read on for all the details.

Monday, May 03, 2021

Informa Connect’s Annual Commercial Contracts & Chargebacks Congress

Informa Connect’s Annual Commercial Contracts & Chargebacks Congress
June 23-25, 2021 | Virtual Event

Informa Connect’s 17th Annual Commercial Contracts & Chargebacks Congress, taking place virtually June 23-25, offers crucial updates on policy changes and contracting best practices to increase efficiency, reduce revenue leakage, and streamline chargeback excellence. 

This annual event has become a must-attend for pricing and contracting professionals in the life sciences industry with seasoned leaders and forward-thinking strategies on display. Join industry stakeholders, including manufacturers, wholesalers, GPOs and more, for a robust three-day event offering extended content and actionable strategies in key interest areas in the ever-evolving contracting landscape.

Drug Channels readers are eligible for an exclusive savings of 10% off* the standard rate by using promo code 21CCCDC10, so download the complete conference agenda and reserve your seat today!

Featured Faculty Driving the Conversation:
  • John Shakow, Partner, King and Spalding
  • Susanne Somerville, Chief Executive Officer, Chronicled
  • Edward McAdam, Director, Government Pricing, Contracting Operations & Analytics, Indivior
  • Mike Domanico, Vice President Finance, Revenue, Sandoz (Novartis)
  • Beth Stevens, Associate Director, Contracts & Pricing, TOLMAR Pharmaceuticals
  • Sherice Koonce, Director of Contracts, Hikma Pharmaceuticals
  • Fred Fieder, Director, Contract Administration, McKesson
  • Susan Lowe, Senior Vice President, Supply Chain Operations, FFF Enterprises
  • Brian Green, Head of Contract Operations, UCB Pharma
  • Felicia Manning, Associate Director, Market Access, Pricing & Reimbursement, Theravance BioPharma US
  • And many more!
Hight Impact Topics Transforming the Market Include:
  • Policy Update on 340B and Pharmacy Channel Evolution
  • Contract Management Reimagined — Operational Excellence Strategies for Increased Process Efficiencies and Reduced Revenue Leakage
  • Strategic Contracting Industry Insights Panel — The Confluence of Data, Financial Analytics and Value
  • Revolutionize and Automate Transactions using Blockchain
  • GPO Panel featuring Vizient, Premier Inc. and more!
  • Contract Administration Industry Insights Panel — Process Improvement in Contract Administration and Management — Streamlining Chargeback Operations, GPO Rosters and Channel Operations
Drug Channels readers are eligible for an exclusive savings of 10% off* the standard rate by using promo code 21CCCDC10, so download the complete conference agenda and reserve your seat today!

*Expires 6/25/20210; applies to standard rate only and may not be combined or applied to existing registrations; other restrictions may apply.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.